Aculeus and Laurus sign CMC development and manufacturing agreement

Aculeus is excited to announce that it has recently signed an agreement with Laurus Synthesis (a CDMO division of Laurus Labs Limited) to undertake Chemistry Manufacturing and Controls (CMC) activities for its advanced preclinical stage STING agonist program. Ultimately, this work will deliver active pharmaceutical ingredient (API) to support both formal toxicology studies and early stage clinical trials and Aculeus looks forward to working with Laurus who have such a strong reputation in the CMC area.